~~<i id='854D7C98FF'><strike id='854D7C98FF'><tt id='854D7C98FF'><pre id='854D7C98FF'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：explore 2025-09-28 12:32:16 Page View：85

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Senators tussle over abortion against the backdrop of a presidential campaign
Next article： Duchenne breakthrough therapy leaves behind pioneering families

explore

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Structure Therapeutics oral GLP

DrewAngerer/GettyImagesStructureTherapeuticsreportedMondaythatitsoralGLP-1drugledtoweightlossintwosm

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

BD to buy Edwards patient monitoring unit for $4.2 billion

IanWaldie/GettyImagesBectonDickinsonplanstopay$4.2billionforEdwardsLifesciences’criticalcarebusiness